Ontology highlight
ABSTRACT: Background
Current treatments for schizophrenia act directly on dopamine (DA) receptors but are ineffective for many patients, highlighting the need to develop new treatment approaches. Striatal DA dysfunction, indexed using [18F]-FDOPA imaging, is linked to the pathoetiology of schizophrenia. We evaluated the effect of a novel drug, AUT00206, a Kv3.1/3.2 potassium channel modulator, on dopaminergic function in schizophrenia and its relationship with symptom change. Additionally, we investigated the test-retest reliability of [18F]-FDOPA PET in schizophrenia to determine its potential as a biomarker for drug discovery.Methods
Twenty patients with schizophrenia received symptom measures and [18F]-FDOPA PET scans, before and after being random
SUBMITTER: Angelescu I
PROVIDER: S-EPMC9554157 | biostudies-literature | 2022 Sep
REPOSITORIES: biostudies-literature